The dopamine D3 receptor (D3R) is
a target for developing medications
to treat substance use disorders. D3R-selective compounds with high
affinity and varying efficacies have been discovered, providing critical
research tools for cell-based studies that have been translated to
in vivo models of drug abuse. D3R antagonists and partial agonists
have shown especially promising results in rodent models of relapse-like
behavior, including stress-, drug-, and cue-induced reinstatement
of drug seeking. However, to date, translation to human studies has
been limited. Herein, we present an overview and illustrate some of
the pitfalls and challenges of developing novel D3R-selective compounds
toward clinical utility, especially for treatment of cocaine abuse.
Future research and development of D3R-selective antagonists and partial
agonists for substance abuse remains critically important but will
also require further evaluation and development of translational animal
models to determine the best time in the addiction cycle to target
D3Rs for optimal therapeutic efficacy.